BEBPA Blog
As part of BEBPA’s mandate to provide forums to foster scientific discussion among biopharmaceutical scientists, we actively write up the results of these discussions. These written updates come in the form of White papers written by a committee of scientists, the results of live interactive surveys and occasionally written reports by attendees. These reports are made available to the public and can be downloaded freely.
Reference Material Day 1 Panel Discussion
A transcript of the Day 1 “Question and Answer Session” from the BEBPA Virtual conference focused on Reference Material for late-stage clinical and commercial pharmaceutical
2025 USB Conference Survey Results (PDF)
BEBPA Blog 2025 USB Conference Survey Results (PDF) View PDF Survey
2025 RFM Conference Survey Results (PDF)
BEBPA Blog 2025 RFM Conference Survey Results (PDF) View PDF Survey
An Interview with BEBPA’s President: Laureen Little, Ph.D.
BEBPA had a chance to sit down with Laureen Little, the President of BEBPA and producer for the upcoming US Bioassay Conference happening March 24-26,
Unveiling Host Cell Protein (HCP) Coverage in Three-Dimensions (3D): Why It Matters and How to Achieve It
Host cell proteins (HCPs) are impurities derived from the host organism used in the production of genetically engineered biopharmaceuticals. Their removal is crucial for the
Beyond Potency: Leveraging Bioassays for Contaminant Testing
Bioassays are used extensively for potency determination of biologic therapeutics. However, ensuring the purity and safety of biologic drugs is of similarly vital importance. Biologic
AI in Bioassay: The Good, The Bad, The Ugly.
For decades, the study and development of AI was reserved to high level academics. Today, much to the amusement of statisticians and data scientists, anybody
Characterization of Precision and Accuracy and Total Analytical Error for Bioassays
We tend to think analytical validation is a fairly straight forward, almost box checking activity if a method is well-developed and suitable for its intended
Tech Briefing: Beyond the Surface: Is Going Deeper Always More Beneficial?
Host cell proteins (HCPs) are residual protein impurities expressed along with the desired biologics product. Removing HCPs in the final drug substance (DS) to an